Advanced search
Start date

Nanoparticles as HIV antigen delivery: potential application in anti-HIV immunotherapy using monocyte-derived dendritic cells

Grant number: 19/24849-1
Support Opportunities:Scholarships in Brazil - Doctorate
Effective date (Start): November 01, 2021
Effective date (End): November 30, 2023
Field of knowledge:Biological Sciences - Immunology - Cellular Immunology
Principal Investigator:Alberto José da Silva Duarte
Grantee:Bruna Tiaki Tiyo
Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Associated research grant:16/25212-9 - Therapeutic vaccine based on aDC1 dendritic cells pulsed with inactivated autologous virus for the control of viremia after ATI in HIV infected individuals, AP.TEM


Immunotherapy based in dendritic cells (CD) is a potential strategy to improve the treatment of HIV infection. Recently, DC has also been attributed the ability to act in the mobilization of viral reservoirs, which could contribute to their elimination, promoting the cure of infection. Unlike conventional Antiretroviral Therapies (ART) aimed at eliminating the virus, immunotherapy is aimed at restoring the immune system of people living with HIV/AIDS (PLWHA), as DCs are capable of capturing antigens, generating cellular response, as well as activating reservoirs of HIV. Therefore, the aim is to stimulate a direct and specific immune response against viral infection. In addition to the importance of the quality of DC to be inoculated in the patient, the type of antigen used to carry MDDC is equally relevant. In this sense, carrier agents have gained notoriety for improving antigen delivery to the cell or tissue of interest. One natural polymer that has been widely studied as an immune system modulator is chitosan. This polysaccharide has advantages such as non-toxicity, biocompatibility and biodegradability. Chitosan nanoparticle has been used mainly in preclinical studies as an antigen and antiretroviral carrier. In addition, research on innovative strategies to contain HIV infection has a great relevance, not only for seeking new alternatives, but also improving the quality of the vaccine product. Thus, the aim of this study is to evaluate the effect of using chitosan nanoparticles for inactivated HIV delivery to pulse MDDC from HIV-1 infected individuals. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list by writing to: